Reported 3 days ago
Pfizer is currently seen as a potentially lucrative investment due to three main factors: its acquisition of Metsera, a company developing promising weight management therapies; a recent deal with the U.S. government granting tariff exemptions; and its attractive stock valuation compared to industry averages. Despite struggling with declining revenue and profits, these developments may position Pfizer on a path to recovery and growth.
Source: YAHOO